GSK-1292263 is a novel GPR119 agonist that is currently under development for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics. Unexpectedly, GSK1292263 lowered fasting LDLc and triglycerides (TG), while increasing HDLc in the diabetic subjects. GSK1292263 has significant effects on plasma lipids and lipoprotein particles in dyslipidemic patients when dosed alone and with atorvastatin.
Properties:
Boiling point: 655.1±65.0 °C(Predicted)
density: 1.23
pka: 4.75±0.32(Predicted)
GPR119 Related Products:
MBX-2982; APD668; AR231453